“Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis” (2018) SKIN The Journal of Cutaneous Medicine, 2, p. S90. doi:10.25251/skin.2.supp.91.